Acacia Pharma initiates Phase IIA study with APD209 in cancer cachexia patients
02-Apr-2009 -
Acacia Pharma announced the initiation of a Phase IIa study of its product APD209 to treat cachexia in cancer patients. APD209 has been designed to target specific problems experienced by cachectic patients, in particular, inadequate nutrition and active muscle breakdown.
Cancer-related cachexia ...
cachexia
cancer cachexia
surgical oncology